Redhill Biopharm SEC Filings

RedHill Biopharma reported receipt of a Nasdaq Staff Determination for continued non-compliance with the minimum stockholders’ equity requirement under Listing Rule 5550(b)(1). The company notes the minimum threshold is $2.5 million and says that, following its transaction with Cumberland Pharmaceuticals announced October 20, 2025, it believes equity now exceeds that level.

RedHill intends to appeal to a Nasdaq Listing Qualifications Panel, which may determine that compliance has been regained or grant up to a 180-day extension. Submission of a hearing request will stay any delisting or suspension action, and RedHill’s American Depositary Shares remain listed and traded on the Nasdaq Capital Market pending the Panel’s decision. The company cautions there is no assurance of a favorable outcome or an extension.

RedHill Biopharma Ltd. filed a prospectus supplement for the resale, from time to time, of up to 4,582,582 American Depositary Shares (ADSs), each representing 10,000 ordinary shares. The registration covers ADSs that may be issued to Alumni Capital LP under an Any Market Purchase Agreement establishing a committed equity line, including up to 333,333 ADSs issuable upon exercise of an unregistered commitment warrant.

The supplement also discloses a Letter Agreement dated October 20, 2025, which increases the beneficial ownership limitation for purchases made via Forward Purchase Notices from 4.99% to 9.99%. Purchases via Regular Purchase Notices remain capped at 4.99%. These limits prevent directing purchases that would result in Alumni and its affiliates exceeding the specified ownership thresholds at any single point in time.

RedHill Biopharma (RDHL) amended its Any Market Purchase Agreement with Alumni Capital to raise the beneficial ownership cap tied to Forward Purchase Notices from 4.99% to 9.99%. The agreement, originally signed on June 20, 2025, allows RedHill to sell up to $10,000,000 of ADSs to Alumni from time to time, at the company’s discretion.

Under a Forward Purchase Notice, Alumni may buy ADSs equal to the lesser of $500,000 or 30% of trading volume on the notice date, priced at the day’s lowest traded price multiplied by 96%. Other purchase types remain subject to a 4.99% ownership cap, with the option for the company to issue prefunded warrants instead of ADSs for Initial or Regular Purchase Notices. The amendment applies only to Forward Purchase Notices and does not change the overall program size.

RedHill Biopharma Ltd. announced a press release included in a Form 6-K describing a new ex‑US licensing deal for its H. pylori therapy Talicia and outlining the drug portfolio and public-health context for H. pylori treatment. The company states a new Middle East agreement includes upfront and milestone payments plus sales royalties totaling approximately $1.8M plus royalties. The release highlights Talicia as the leading branded H. pylori therapy among U.S. gastroenterologists, patent protection through 2042, and 8 years of U.S. market exclusivity under QIDP designation.

The filing summarizes H. pylori prevalence and risks: ~35 of U.S. adults (~1.6M treated annually), >50 globally, and up to ~80 in parts of the Middle East; H. pylori is linked to ~800,000 global deaths annually and ~27,000 U.S. gastric cancer diagnoses per year. The release notes rising antibiotic resistance and that current therapies fail in roughly 25-40 of patients, supporting the need for Talicia's rifabutin‑based regimen. The document also lists other pipeline assets and standard forward‑looking statements.

RedHill Biopharma Ltd. filed a Form 6-K attaching a press release that reports a New York Supreme Court appeal decision upholding a $10 million summary judgment in the company’s favor against Kukbo. The filing reiterates RedHill’s corporate registration details and lists recent and prior registration statements incorporated by reference. The document also summarizes RedHill’s clinical-stage pipeline, including opaganib (ABC294640) (multiple indications including GI-ARS, hospitalized COVID-19, prostate cancer), RHB-204 (planned Phase 2 for Crohn’s disease; Phase 3-stage for pulmonary NTM), RHB-107 (upamostat) (late-stage for non-hospitalized COVID-19 and other indications), and RHB-102 (positive Phase 2/3 results for GI indications; partnered with Hyloris Pharma). The filing contains no financial results or quantified impact of the judgment.

RedHill Biopharma Ltd. announced that the New York Supreme Court awarded the company approximately $1.82 million in legal costs and expenses, in addition to a prior summary judgment award of approximately $8.25 million, with a 9% ongoing statutory interest applicable to both awards. The company also obtained a court-ordered attachment from Korea's Incheon District Court to seize Kukbo Co. Ltd.'s assets pending enforcement. Kukbo appealed the summary judgment on December 4, 2024, and briefing on that appeal is complete with oral argument tentatively scheduled for the September term; Kukbo may also appeal the legal-costs award. The release reiterates RedHill's clinical and commercial programs and includes standard forward-looking risk disclosures.

RedHill Biopharma reported receipt of its first ex-U.S. Talicia sales milestone, royalties and other payments totaling approximately $1.1 million following Talicia's first commercial launch outside the U.S. in 2024. Talicia is an FDA-approved, rifabutin-based therapy for H. pylori, a common infection affecting over 50% of adults worldwide and a major risk factor for gastric cancer and peptic ulcers. The product has QIDP designation providing up to eight years of U.S. exclusivity and patent protection through 2042. RedHill said Talicia showed up to 90% eradication in adherent patients in Phase 3 and contrasted this with lower effectiveness of clarithromycin-based regimens.